Genotyping and the Future of Transfusion in Sickle Cell Disease

Matthew S Karafin; Jo Howard

doi:10.1016/j.hoc.2022.07.012

Genotyping and the Future of Transfusion in Sickle Cell Disease

Hematol Oncol Clin North Am. 2022 Dec;36(6):1271-1284. doi: 10.1016/j.hoc.2022.07.012.

Authors

Matthew S Karafin¹, Jo Howard²

Affiliations

¹ Department of Pathology and Laboratory Medicine, University of North Carolina, 101 Manning Drive, Chapel Hill, NC, USA. Electronic address: [email protected].
² Department of Haematology, Guy's and St Thomas' Hospital, Great Maze Pond, London, SE1 9RT, UK; Department of Haematological Medicine, King's College London, London, SE5 9RS, UK.

PMID: 36400543
DOI: 10.1016/j.hoc.2022.07.012

Abstract

Patients with sickle cell disease (SCD) have a high rate of red cell alloimmunization, which increases morbidity and mortality. Reasons for this susceptibility are multifactorial, but differences in antigen frequency between donors and recipients are one of the modifiable risk factors. Here, we evaluate the benefits of red cell molecular antigen-typing for both patients with SCD and their donors and describe how results from these critical tests could be used to enhance patient safety.

Keywords: Alloimmunization; Chronic transfusion; Genotyping; Molecular antigen typing; Red cell transfusion; Sickle cell disease.

Publication types

Review

MeSH terms

Anemia, Sickle Cell* / genetics
Anemia, Sickle Cell* / therapy
Blood Transfusion
Erythrocytes
Genotype
Humans
Isoantibodies*

Substances

Isoantibodies